Avacta Group plc (GB:AVCT) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Avacta Group plc has appointed Dr. Christina Coughlin as its new CEO, effective May 1, 2024. Dr. Coughlin brings extensive experience in oncology and biopharmaceuticals, having served as a board member and head of R&D, where she advanced the development of their pre|CISION platform for cancer treatment. The company is poised for its next clinical development phase, focusing on delivering innovative cancer therapies and enhancing shareholder value.
For further insights into GB:AVCT stock, check out TipRanks’ Stock Analysis page.
